Seguir
Dejan Juric
Dejan Juric
Massachusetts General Hospital
Dirección de correo verificada de mgh.harvard.edu
Título
Citado por
Citado por
Año
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ...
New England Journal of Medicine 380 (20), 1929-1940, 2019
19632019
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
6662018
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
TM Delorey, CGK Ziegler, G Heimberg, R Normand, Y Yang, ...
Nature 595 (7865), 107-113, 2021
5862021
Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor
D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ...
Nature 518 (7538), 240-244, 2015
5692015
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ...
Cancer discovery 7 (3), 252-263, 2017
4552017
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh, C Costa, ...
Cancer cell 26 (1), 136-149, 2014
4412014
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ...
Nature medicine 25 (9), 1415-1421, 2019
3992019
Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer
A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, ...
Journal of Clinical Oncology 35 (19), 2141, 2017
3682017
Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas
M Bredel, C Bredel, D Juric, GR Harsh, H Vogel, LD Recht, BI Sikic
Cancer research 65 (19), 8679-8689, 2005
3582005
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final overall survival …
F André, EM Ciruelos, D Juric, S Loibl, M Campone, IA Mayer, ...
Annals of Oncology 32 (2), 208-217, 2021
3502021
Phosphatidylinositol 3-kinase α–selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study
D Juric, J Rodon, J Tabernero, F Janku, HA Burris, JHM Schellens, ...
Journal of Clinical Oncology 36 (13), 1291, 2018
3472018
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2 Metastatic Breast Cancer
IA Mayer, VG Abramson, L Formisano, JM Balko, MV Estrada, ...
Clinical cancer research 23 (1), 26-34, 2017
3352017
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ...
Science translational medicine 5 (196), 196ra99-196ra99, 2013
3102013
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
M Elkabets, E Pazarentzos, D Juric, Q Sheng, RA Pelossof, S Brook, ...
Cancer cell 27 (4), 533-546, 2015
3082015
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
2742019
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ...
Cancer discovery 11 (8), 1913-1922, 2021
2672021
CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer
SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ...
Cell reports 17 (9), 2367-2381, 2016
2592016
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
H Ebi, C Costa, AC Faber, M Nishtala, H Kotani, D Juric, P Della Pelle, ...
Proceedings of the National Academy of Sciences 110 (52), 21124-21129, 2013
2342013
Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection
N Desai, A Neyaz, A Szabolcs, AR Shih, JH Chen, V Thapar, LT Nieman, ...
Nature communications 11 (1), 6319, 2020
2212020
Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: a phase 1b clinical trial
D Juric, F Janku, J Rodón, HA Burris, IA Mayer, M Schuler, ...
JAMA oncology 5 (2), e184475-e184475, 2019
2202019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20